162 related articles for article (PubMed ID: 31842875)
1. RNA disruption indicates CHOP therapy efficacy in canine lymphoma.
Parissenti AM; Pritzker LB; Guo B; Narendrula R; Wang SX; Lin LL; Pei J; Skowronski K; Bienzle D; Woods JP; Pritzker KPH; Coomber BL
BMC Vet Res; 2019 Dec; 15(1):453. PubMed ID: 31842875
[TBL] [Abstract][Full Text] [Related]
2. Substitution of mitoxantrone for doxorubicin in a multidrug chemotherapeutic protocol for first-line treatment of dogs with multicentric intermediate- to large-cell lymphoma.
Marquardt TM; Lindley SES; Smith AN; Cannon CM; Rodriguez CO; Thamm DH; Childress MO; Northrup NC
J Am Vet Med Assoc; 2019 Jan; 254(2):236-242. PubMed ID: 30605381
[TBL] [Abstract][Full Text] [Related]
3. Assessment of temporal association of relapse of canine multicentric lymphoma with components of the CHOP protocol: Is cyclophosphamide the weakest link?
Wang SL; Lee JJ; Liao AT
Vet J; 2016 Jul; 213():87-9. PubMed ID: 27240922
[TBL] [Abstract][Full Text] [Related]
4. Geographical differences in survival of dogs with non-Hodgkin lymphoma treated with a CHOP based chemotherapy protocol.
Wilson-Robles H; Budke CM; Miller T; Dervisis N; Novosad A; Wright Z; Thamm DH; Vickery K; Burgess K; Childress M; Lori J; Saba C; Rau S; Silver M; Post G; Reeds K; Gillings S; Schleis S; Stein T; Brugmann B; DeRegis C; Smrkovski O; Lawrence J; Laver T
Vet Comp Oncol; 2017 Dec; 15(4):1564-1571. PubMed ID: 28419683
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of factors associated with second remission in dogs with lymphoma undergoing retreatment with a cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy protocol: 95 cases (2000-2007).
Flory AB; Rassnick KM; Erb HN; Garrett LD; Northrup NC; Selting KA; Phillips BS; Locke JE; Chretin JD
J Am Vet Med Assoc; 2011 Feb; 238(4):501-6. PubMed ID: 21320021
[TBL] [Abstract][Full Text] [Related]
6. Comparison of efficacy and toxicity of doxorubicin and mitoxantrone in combination chemotherapy for canine lymphoma.
Wang SL; Lee JJ; Liao AT
Can Vet J; 2016 Mar; 57(3):271-6. PubMed ID: 26933263
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA profiling in canine multicentric lymphoma.
Craig KKL; Wood GA; Keller SM; Mutsaers AJ; Wood RD
PLoS One; 2019; 14(12):e0226357. PubMed ID: 31826004
[TBL] [Abstract][Full Text] [Related]
8. CHOP chemotherapy for the treatment of canine multicentric T-cell lymphoma.
Rebhun RB; Kent MS; Borrofka SA; Frazier S; Skorupski K; Rodriguez CO
Vet Comp Oncol; 2011 Mar; 9(1):38-44. PubMed ID: 21303452
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a 15-week CHOP protocol for the treatment of canine multicentric lymphoma.
Burton JH; Garrett-Mayer E; Thamm DH
Vet Comp Oncol; 2013 Dec; 11(4):306-15. PubMed ID: 22548975
[TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis for treatment of naïve canine multicentric lymphoma with a 15-week, maintenance-free CHOP protocol.
Curran K; Thamm DH
Vet Comp Oncol; 2016 Aug; 14 Suppl 1():147-55. PubMed ID: 26279153
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP-MA) for the treatment of canine lymphoma.
Daters AT; Mauldin GE; Mauldin GN; Brodsky EM; Post GS
Vet Comp Oncol; 2010 Mar; 8(1):11-22. PubMed ID: 20230577
[TBL] [Abstract][Full Text] [Related]
12. The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates.
Peters FP; Fickers MM; Erdkamp FL; Wals J; Wils JA; Schouten HC
Ann Hematol; 2001 Jul; 80(7):406-10. PubMed ID: 11529466
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a multi-agent chemotherapy protocol combining lomustine, procarbazine and prednisolone (LPP) for the treatment of relapsed canine non-Hodgkin high-grade lymphomas.
Tanis JB; Mason SL; Maddox TW; Blackwood L; Killick DR; Amores-Fuster I; Harper A; Finotello R
Vet Comp Oncol; 2018 Sep; 16(3):361-369. PubMed ID: 29380942
[TBL] [Abstract][Full Text] [Related]
14. Increased monocyte chemotactic protein-1 concentration and monocyte count independently associate with a poor prognosis in dogs with lymphoma.
Perry JA; Thamm DH; Eickhoff J; Avery AC; Dow SW
Vet Comp Oncol; 2011 Mar; 9(1):55-64. PubMed ID: 21303454
[TBL] [Abstract][Full Text] [Related]
15. CHOP chemotherapy with preemptive granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma: a dose-intensity analysis.
Jacobson JO; Grossbard M; Shulman LN; Neuberg D
Clin Lymphoma; 2000 Dec; 1(3):211-7; discussion 218. PubMed ID: 11707832
[TBL] [Abstract][Full Text] [Related]
16. Fourteen-day CHOP supported with granulocyte colony-stimulating factor in patients with aggressive non-Hodgkin's lymphoma: results of a phase II study.
Gregory SA; Case DC; Bosserman L; Litwak DL; Berry WR; Kalman LA; Belt RJ; Saven A
Clin Lymphoma; 2003 Sep; 4(2):93-8. PubMed ID: 14556680
[TBL] [Abstract][Full Text] [Related]
17. Advances in chemotherapy for large cell lymphoma.
Coleman M; Gerstein G; Topilow A; Lebowicz J; Berhardt B; Chiarieri D; Silver RT; Pasmantier MW
Semin Hematol; 1987 Apr; 24(2 Suppl 1):8-20. PubMed ID: 2438781
[TBL] [Abstract][Full Text] [Related]
18. Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma.
Coiffier B
Semin Oncol; 2004 Feb; 31(1 Suppl 2):7-11. PubMed ID: 15042528
[TBL] [Abstract][Full Text] [Related]
19. Retrospective analysis of factors affecting clinical outcome following CHOP-based chemotherapy in dogs with primary nodal diffuse large B-cell lymphoma.
Childress MO; Ramos-Vara JA; Ruple A
Vet Comp Oncol; 2018 Mar; 16(1):E159-E168. PubMed ID: 29152834
[TBL] [Abstract][Full Text] [Related]
20. Effect of proteasome inhibitors on canine lymphoma cell response to CHOP chemotherapy in vitro.
Prevedel NE; Mee MW; Wood GA; Coomber BL
Vet Comp Oncol; 2024 Mar; 22(1):96-105. PubMed ID: 38237918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]